Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV iron implementation for maternal anaemia in Bangladesh primary care
ACTRN12623001163695Phase 4Not yet recruiting
- Sponsor
- icddr,b
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric carboxymaltose in anaemia, iron deficiency anemia (IDA) and pregnancy, sponsored by icddr,b. Primary endpoint: Proportion of identified pregnant women with moderate or severe anaemia who received IV iron in primary care. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemiairon deficiency anemia (IDA)pregnancy
Beyond the preview
Go deeper on ACTRN12623001163695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001163695.